Researchers at Weill Cornell Medical College have developed and successfully tested in mice an innovative vaccine to treat nicotine addiction.
In the journal Science Translational Medicine, the scientists describe how a single dose of their novel vaccine protects mice, over their lifetime, against nicotine addiction. The vaccine is designed to use the animal’s liver as a factory to continuously produce antibodies that gobble up nicotine the moment it enters the bloodstream, preventing the chemical from reaching the brain and even the heart.
"As far as we can see, the best way to treat chronic nicotine addiction from smoking is to have these Pacman-like antibodies on patrol, clearing the blood as needed before nicotine can have any biological effect," says the study’s lead investigator, Dr. Ronald G. Crystal, chairman and professor of Genetic Medicine at Weill Cornell Medical College.
"Our vaccine allows the body to make its own monoclonal antibodies against nicotine, and in that way, develop a workable immunity," Dr. Crystal says.
Full story of nicotine addiction vaccine at Science Daily
Photos courtesy of and copyright stock.xchng, http://www.sxc.hu/
By Michelle Fay Cortez
Nicotine-replacing gums and patches like those from GlaxoSmithKline Plc and Pfizer Inc. failed to help smokers who quit the habit stay off cigarettes, even when used with professional counseling, a study found.
Researchers surveying 781 former smokers found almost a third relapsed even after using nicotine replacement products. Scientists said the results cast doubt on the long-term benefit of products like Pfizer’s Nicotrol inhaler and GlaxoSmithKline’s NicoDerm CQ patch and Nicorette gum, leaders in a market worth $1.2 billion annually, according to IMS Health, a research firm.
The U.S. Food and Drug Administration should only approve products that have been shown to help smokers quit and stay off cigarettes for years, said researcher Gregory Connolly, director of the Center for Global Tobacco Control at Harvard School of Public Health, in a statement.
“Using nicotine replacement therapy is no more effective in helping people stop smoking cigarettes in the long-term than trying to quit on one’s own,” said lead author Hillel Alpert, a Harvard research scientist.
Full story at Bloomberg Businessweek